| Literature DB >> 25660838 |
Alessandra Dei Cas1, Sadiya S Khan2, Javed Butler3, Robert J Mentz4, Robert O Bonow5, Angelo Avogaro6, Diethelm Tschoepe7, Wolfram Doehner8, Stephen J Greene5, Michele Senni9, Mihai Gheorghiade5, Gregg C Fonarow10.
Abstract
The prevalence of patients with concomitant heart failure (HF) and diabetes mellitus (DM) continues to increase with the general aging of the population. In patients with chronic HF, prevalence of DM is 24% compared with 40% in those hospitalized with worsening HF. Patients with concomitant HF and DM have diverse pathophysiologic, metabolic, and neurohormonal abnormalities that potentially contribute to worse outcomes than those without comorbid DM. In addition, although stable HF outpatients with DM show responses that are similar to those of patients without DM undergoing evidence-based therapies, it is unclear whether hospitalized HF patients with DM will respond similarly to novel investigational therapies. These data support the need to re-evaluate the epidemiology, pathophysiology, and therapy of HF patients with concomitant DM. This paper discusses the role of DM in HF patients and underscores the potential need for the development of targeted therapies.Entities:
Keywords: diabetes mellitus; diabetic cardiomyopathy; heart failure
Mesh:
Substances:
Year: 2015 PMID: 25660838 DOI: 10.1016/j.jchf.2014.08.004
Source DB: PubMed Journal: JACC Heart Fail ISSN: 2213-1779 Impact factor: 12.035